We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

17 hedge funds and large institutions have $4.16M invested in Benitec Biopharma in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

0.05% more ownership

Funds ownership: 1.1% → 1.15% (+0.05%)

6% less funds holding

Funds holding: 18 → 17 (-1)

23% less capital invested

Capital invested by funds: $5.43M → $4.16M (-$1.26M)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Silverarc Capital Management
Massachusetts
+$294K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$15.5K
3
UBS Group
UBS Group
Switzerland
+$6.76K
4
BlackRock
BlackRock
New York
+$1.73K
5
CCM
Chilton Capital Management
Texas
+$223

Top Sellers

Rank Fund Capital Flow
1
PWAC
Private Wealth Advisors (California)
California
-$49K
2
VF
Virtu Financial
New York
-$40.9K
3
RE
RBC Europe
United Kingdom
-$21
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Suvretta Capital Management
New York
$2.02M – – –
SCM
2
Silverarc Capital Management
Massachusetts
$1.54M +$294K +5,264 +18%
Vanguard Group
3
Vanguard Group
Pennsylvania
$205K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$153K +$15.5K +278 +9%
State Street
5
State Street
Massachusetts
$55K – – –
BlackRock
6
BlackRock
New York
$53K +$1.73K +31 +3%
Bank of New York Mellon
7
Bank of New York Mellon
New York
$39K – – –
WA
8
WealthTrust Axiom
Pennsylvania
$33K – – –
Northern Trust
9
Northern Trust
Illinois
$31K – – –
VF
10
Virtu Financial
New York
$27K -$40.9K -733 -54%
UBS Group
11
UBS Group
Switzerland
$8K +$6.76K +121 +195%
Group One Trading
12
Group One Trading
Illinois
$5K – – –
MHR
13
Matthew Hamilton Rosenberg
$1K – – –
PWAC
14
Private Wealth Advisors (California)
California
– -$49K -885 Closed
RE
15
RBC Europe
United Kingdom
– -$21 – –
Wells Fargo
16
Wells Fargo
California
– +$56 +1 +50%
CCM
17
Chilton Capital Management
Texas
– +$223 +4 New

BNTC Hedge Fund Activity: Q4 2021 in Review

17 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2021, worth a combined $4.16M — down 23% from $5.43M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BNTC and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.

The largest buyer was Silverarc Capital Management, adding an estimated $294K. The largest seller was Private Wealth Advisors (California), exiting entirely with an estimated $49K sold.

  • 17 institutional investors held Benitec Biopharma (BNTC) as of Q4 2021, down from 18 in Q3 2021.
  • Funds reported $4.16M of Benitec Biopharma stock for Q4 2021, down 23% quarter-over-quarter.
  • 1 fund opened new Benitec Biopharma positions in Q4 2021 and 2 closed out, a net change of -1 holder.
  • The largest Benitec Biopharma buyer in Q4 2021 was Silverarc Capital Management, an estimated $294K added.
  • The largest Benitec Biopharma seller in Q4 2021 was Private Wealth Advisors (California), an estimated $49K sold.

Based on aggregated 13F filings for Q4 2021.